3 results
See protocol page 9This study designed to determine, via continuous monitoring with the Reveal XT implantable cardiac monitor (ICM) or newer approved version, the incidence of atrial fibrillation (AF) in patients suspected to be at high risk for…
The aim of this study is to investigate how quickly and to what extent aticaprant is absorbed, transported, and eliminated from the body (this is called pharmacokinetics). For this study, aticaprant is radioactively labelled with carbon-14 (14C). In…
To evaluate the relative oral bioavailability and dose proportionality of concept formulations compared with the reference formulation of aticaprant when administered in healthy adult participants. This part will be conducted by PRA.To evaluate the…